Association of ventricular-arterial coupling with biomarkers involved in heart failure pathophysiology - the STANISLAS cohort.
Cardiovascular
Echocardiography
Hypertension
Ventricular–arterial coupling
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
revised:
21
07
2024
received:
15
01
2024
accepted:
25
07
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
27
8
2024
Statut:
aheadofprint
Résumé
Impaired left ventricular-arterial coupling (VAC) has been shown to correlate with worse prognosis in cardiac diseases and heart failure (HF). The extent of the relationship between VAC and circulating biomarkers associated with HF has been scarcely documented. We aimed to explore associations of VAC with proteins involved in HF pathophysiology within a large population-based cohort of middle-aged individuals. In the forth visit of the STANISLAS family cohort, involving 1309 participants (mean age 48 ± 14 years; 48% male) from parent and children generations, we analysed the association of 32 HF-related proteins with non-invasively assessed VAC using pulse wave velocity (PWV)/global longitudinal strain (GLS) and arterial elastance (E Elevated MMP-2 and NT-proBNP levels correlate with better VAC (lower PWV/GLS), possibly indicating a compensatory cardiovascular response to regulate left ventricular pressure amidst cardiac remodelling and overload.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Swedish Medical Research Council
Organisme : Swedish Heart and Lung Foundation
Organisme : Skåne University Hospital
Organisme : Crafoord Foundation
Organisme : Knut and Alice Wallenberg Foundation and the Marianne and Marcus Wallenberg Foundation
Organisme : Wallenberg Centre for Molecular Medicine at Lund University. N.G
Organisme : P.R. are supported by public grants overseen by the European Commission
Organisme : French National Research Agency Fighting Heart Failure
ID : ANR-15-RHU-0004
Informations de copyright
© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Ikonomidis I, Aboyans V, Blacher J, Brodmann M, Brutsaert DL, Chirinos JA, et al. The role of ventricular‐arterial coupling in cardiac disease and heart failure: Assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association. Eur J Heart Fail 2019;21:402–424. https://doi.org/10.1002/ejhf.1436
Chen CH, Fetics B, Nevo E, Rochitte CE, Chiou KR, Ding PA, et al. Noninvasive single‐beat determination of left ventricular end‐systolic elastance in humans. J Am Coll Cardiol 2001;38:2028–2034. https://doi.org/10.1016/s0735‐1097(01)01651‐5
Coutinho T, Borlaug BA, Pellikka PA, Turner ST, Kullo IJ. Sex differences in arterial stiffness and ventricular‐arterial interactions. J Am Coll Cardiol 2013;61:96–103. https://doi.org/10.1016/j.jacc.2012.08.997
Chirinos JA, Rietzschel ER, Shiva‐Kumar P, De Buyzere ML, Zamani P, Claessens T, et al. Effective arterial elastance is insensitive to pulsatile arterial load. Hypertension 2014;64:1022–1031. https://doi.org/10.1161/HYPERTENSIONAHA.114.03696
Ikonomidis I, Katsanos S, Triantafyllidi H, Parissis J, Tzortzis S, Pavlidis G, et al. Pulse wave velocity to global longitudinal strain ratio in hypertension. Eur J Clin Invest 2019;49:e13049. https://doi.org/10.1111/eci.13049
Pugliese NR, Balletti A, Armenia S, De Biase N, Faita F, Mengozzi A, et al. Ventricular‐arterial coupling derived from proximal aortic stiffness and aerobic capacity across the heart failure Spectrum. JACC Cardiovasc Imaging 2022;15:1545–1559. https://doi.org/10.1016/j.jcmg.2022.03.024
Holm H, Magnusson M, Jujic A, Pugliese NR, Bozec E, Lamiral Z, et al. Ventricular‐arterial coupling (VAC) in a population‐based cohort of middle‐aged individuals: The STANISLAS cohort. Atherosclerosis 2023;374:11–20. https://doi.org/10.1016/j.atherosclerosis.2023.04.010
Chirinos JA, Sweitzer N. Ventricular‐arterial coupling in chronic heart failure. Card Fail Rev 2017;3:12–18. https://doi.org/10.15420/cfr.2017:4:2
Kobayashi M, Huttin O, Magnusson M, Ferreira JP, Bozec E, Huby AC, et al.; STANISLAS Study Investigators. Machine learning‐derived echocardiographic phenotypes predict heart failure incidence in asymptomatic individuals. JACC Cardiovasc Imaging 2022;15:193–208. https://doi.org/10.1016/j.jcmg.2021.07.004
Ferreira JP, Girerd N, Bozec E, Merckle L, Pizard A, Bouali S, et al. Cohort profile: Rationale and design of the fourth visit of the STANISLAS cohort: A familial longitudinal population‐based cohort from the Nancy region of France. Int J Epidemiol 2018;47:395–395j. https://doi.org/10.1093/ije/dyx240
Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid‐femoral pulse wave velocity. J Hypertens 2012;30:445–448. https://doi.org/10.1097/HJH.0b013e32834fa8b0
Yang H, Wright L, Negishi T, Negishi K, Liu J, Marwick TH. Research to practice: Assessment of left ventricular global longitudinal strain for surveillance of cancer chemotherapeutic‐related cardiac dysfunction. JACC Cardiovasc Imaging 2018;11:1196–1201. https://doi.org/10.1016/j.jcmg.2018.07.005
Coiro S, Huttin O, Bozec E, Selton‐Suty C, Lamiral Z, Carluccio E, et al. Reproducibility of echocardiographic assessment of 2D‐derived longitudinal strain parameters in a population‐based study (the STANISLAS cohort study). Int J Cardiovasc Imaging 2017;33:1361–1369. https://doi.org/10.1007/s10554‐017‐1117‐z
Chang MC, Mondy JS 3rd, Meredith JW, Miller PR, Owings JT, Holcroft JW. Clinical application of ventricular end‐systolic elastance and the ventricular pressure‐volume diagram. Shock 1997;7:413–419. https://doi.org/10.1097/00024382‐199706000‐00003
Enroth S, Maturi V, Berggrund M, Enroth SB, Moustakas A, Johansson A, et al. Systemic and specific effects of antihypertensive and lipid‐lowering medication on plasma protein biomarkers for cardiovascular diseases. Sci Rep 2018;8:5531. https://doi.org/10.1038/s41598‐018‐23860‐y
Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 2011;13:1087–1095. https://doi.org/10.1093/eurjhf/hfr079
Hage C, Michaelsson E, Linde C, Donal E, Daubert JC, Gan LM, et al. Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: A holistic proteomic approach. Circ Cardiovasc Genet 2017;10:e001633. https://doi.org/10.1161/CIRCGENETICS.116.001633
Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–271. https://doi.org/10.1016/j.jacc.2013.02.092
Sabbah MS, Fayyaz AU, de Denus S, Felker GM, Borlaug BA, Dasari S, et al. Obese‐inflammatory phenotypes in heart failure with preserved ejection fraction. Circ Heart Fail 2020;13:e006414. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006414
Tromp J, Khan MA, Klip IT, Meyer S, de Boer RA, Jaarsma T, et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc 2017;6:e003989. https://doi.org/10.1161/JAHA.116.003989
Sanders‐van Wijk S, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, et al.; TIME‐CHF investigators. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail 2015;17:1006–1014. https://doi.org/10.1002/ejhf.414
Girerd N, Bresso E, Devignes MD, Rossignol P. Insulin‐like growth factor binding protein 2: A prognostic biomarker for heart failure hardly redundant with natriuretic peptides. Int J Cardiol 2020;300:252–254. https://doi.org/10.1016/j.ijcard.2019.11.100
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta‐Cepas J, et al. STRING v11: Protein‐protein association networks with increased coverage, supporting functional discovery in genome‐wide experimental datasets. Nucleic Acids Res 2019;47:D607–D613. https://doi.org/10.1093/nar/gky1131
Fabregat A, Korninger F, Viteri G, Sidiropoulos K, Marin‐Garcia P, Ping P, et al. Reactome graph database: Efficient access to complex pathway data. PLoS Comput Biol 2018;14:e1005968. https://doi.org/10.1371/journal.pcbi.1005968
Ferreira JP, Lamiral Z, Xhaard C, Duarte K, Bresso E, Devignes MD, et al. Circulating plasma proteins and new‐onset diabetes in a population‐based study: Proteomic and genomic insights from the STANISLAS cohort. Eur J Endocrinol 2020;183:285–295. https://doi.org/10.1530/EJE‐20‐0246
Bauvois B. New facets of matrix metalloproteinases MMP‐2 and MMP‐9 as cell surface transducers: Outside‐in signaling and relationship to tumor progression. Biochim Biophys Acta 2012;1825:29–36. https://doi.org/10.1016/j.bbcan.2011.10.001
Kobusiak‐Prokopowicz M, Krzysztofik J, Kaaz K, Jolda‐Mydlowska B, Mysiak A. MMP‐2 and TIMP‐2 in patients with heart failure and chronic kidney disease. Open Med (Wars) 2018;13:237–246. https://doi.org/10.1515/med‐2018‐0037
George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase‐2 but not matrix metalloproteinase‐3, matrix metalloproteinase‐9, or tissue inhibitor of metalloproteinase‐1 predicts outcome in patients with congestive heart failure. Am Heart J 2005;150:484–487. https://doi.org/10.1016/j.ahj.2004.11.016
Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T. Circulating matrix metalloproteinase‐2 is elevated in patients with congestive heart failure. Eur J Heart Fail 2004;6:41–45. https://doi.org/10.1016/j.ejheart.2003.05.002
Goncalves PR, Nascimento LD, Gerlach RF, Rodrigues KE, Prado AF. Matrix metalloproteinase 2 as a pharmacological target in heart failure. Pharmaceuticals (Basel) 2022;15:920. https://doi.org/10.3390/ph15080920
Wang M, Kim SH, Monticone RE, Lakatta EG. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension 2015;65:698–703. https://doi.org/10.1161/HYPERTENSIONAHA.114.03618
Matsusaka H, Ikeuchi M, Matsushima S, Ide T, Kubota T, Feldman AM, et al. Selective disruption of MMP‐2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine‐induced cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289:H1858–H1864. https://doi.org/10.1152/ajpheart.00216.2005
Jhund PS, Anand IS, Komajda M, Claggett BL, McKelvie RS, Zile MR, et al. Changes in N‐terminal pro‐B‐type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: An analysis of the I‐Preserve study. Eur J Heart Fail 2015;17:809–817. https://doi.org/10.1002/ejhf.274
Edvinsson ML, Uddman E, Edvinsson L, Andersson SE. Brain natriuretic peptide is a potent vasodilator in aged human microcirculation and shows a blunted response in heart failure patients. J Geriatr Cardiol 2014;11:50–56. https://doi.org/10.3969/j.issn.1671‐5411.2014.01.004
Pareek M, Bhatt DL, Vaduganathan M, Biering‐Sørensen T, Qamar A, Diederichsen AC, et al. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. Eur J Prev Cardiol 2017;24:1648–1659. https://doi.org/10.1177/2047487317717065
Paget V, Legedz L, Gaudebout N, Girerd N, Bricca G, Milon H, et al. N‐terminal pro‐brain natriuretic peptide: A powerful predictor of mortality in hypertension. Hypertension 2011;57:702–709. https://doi.org/10.1161/HYPERTENSIONAHA.110.163550
Fradley MG, Larson MG, Cheng S, McCabe E, Coglianese E, Shah RV, et al. Reference limits for N‐terminal‐pro‐B‐type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 2011;108:1341–1345. https://doi.org/10.1016/j.amjcard.2011.06.057
Monzo L, Reichenbach A, Al‐Hiti H, Borlaug BA, Havlenova T, Solar N, et al. Acute unloading effects of sildenafil enhance right ventricular‐pulmonary artery coupling in heart failure. J Card Fail 2021;27:224–232. https://doi.org/10.1016/j.cardfail.2020.11.007
Nissinen L, Kahari VM. Matrix metalloproteinases in inflammation. Biochim Biophys Acta 2014;1840:2571–2580. https://doi.org/10.1016/j.bbagen.2014.03.007
Fish‐Trotter H, Ferguson JF, Patel N, Arora P, Allen NB, Bachmann KN, et al. Inflammation and circulating natriuretic peptide levels. Circ Heart Fail 2020;13:e006570. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006570
Oeckinghaus A, Ghosh S. The NF‐kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009;1:a000034. https://doi.org/10.1101/cshperspect.a000034
Podzolkov VI, Nebieridze NN, Safronova TA. Transforming growth factor‐beta1, arterial stiffness and vascular age in patients with uncontrolled arterial hypertension. Heart Lung Circ 2021;30:1769–1777. https://doi.org/10.1016/j.hlc.2021.06.524